Weight-Loss Drug Wegovy Considerably Reduces Obsessive Food Thoughts, Novo Nordisk Study Reveals
VIENNA, Austria – A new american survey presented at the European Association for the study of Diabetes (EASD 2025) in Vienna demonstrates that the weight-management medication semaglutide (Wegovy) substantially reduces intrusive thoughts about food, alongside improvements in mental well-being and lifestyle habits. The findings, released by Novo Nordisk, suggest the drug’s benefits extend beyond weight loss to address the psychological challenges associated with obesity.
The study revealed a 46% decrease in participants experiencing constant thinking about food,dropping from 62% before treatment to 16% while using Wegovy. Furthermore, the percentage of participants reporting these thoughts negatively impacting their daily lives fell from 60% to 20%. This reduction in “annoying nutritional ideas” – persistent, unwanted thoughts about food – is meaningful as these thoughts are known to negatively affect mental health, quality of life, and weight-loss efforts.
According to the data, 64% of participants reported improved psychological health sence beginning treatment, while 76% adopted a healthier lifestyle and 80% reported better eating habits. An notable 83% of participants expressed full satisfaction with their Wegovy treatment.
“There are several factors that hinder weight loss efforts, among them annoying nutritional ideas,” stated Philip Konop, Senior Vice President and Head of Medical and Transformative sciences at Novo Nordisk. “It is encouraging to show this data that Wegovy is not limited to weight loss, but also helps to calm negative thinking about food, improving mental health, and enabling people to live a healthier life.”
Novo Nordisk continues to investigate the broader impact of obesity on individuals’ lives. Additional presentations at EASD 2025 included results from the step UP clinical trial, examining eating patterns and appetite control with semaglutide, adding to the growing body of evidence supporting the drug’s complete health benefits.
